Clinical characteristics and prognosis analysis of acute myeloid leukemia patients with PTPN11 gene mutation
10.19405/j.cnki.issn1000-1492.2024.08.029
- Author:
Qianshan Tao
1
;
Wanying Xue
1
;
Beibei Xie
1
;
Qing Zhang
1
;
Huiping Wang
1
;
Zhimin Zhai
1
;
Hui Qin
1
;
Yi Dong
1
Author Information
1. Dept of Hematology，The Second Affiliated Hospital of Anhui Medical University，Hefei 230601
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
gene mutation;
PTPN11;
prognosis
- From:
Acta Universitatis Medicinalis Anhui
2024;59(8):1483-1488,1494
- CountryChina
- Language:Chinese
-
Abstract:
Objective :To investigate the clinical characteristics and prognosis of acute myeloid leukemia ( AML) patients with PTPN11 gene mutation．
Methods :Total 115 adult AML patients who underwent initial diagnosis， treatment，and second-generation sequencing (NGS) detecting at hospital were recruited in this study．Clinical da- ta included disease characteristics，treatment efficacy，long-term prognosis，immune cell subpopulations，and leu- kemia stem cells were collected to analyze the clinical characteristics and prognosis of AML patients with PTPN11 gene mutation.
Results :PTPN11 gene mutation rate in newly diagnosed adult AML was 9. 57% ，and the mutation site mainly occurred in exon 3 region with all mutation type being point mutation． Compared with PTPN11 wild- type group，PTPN11 gene mutation group had a higher early mortality rate ( 18. 18% vs 4. 00% ，P = 0. 048) ，a lower complete response rate (33. 33% vs 67. 71% ，P = 0. 039) ，a higher recurrence rate (83. 33% vs 42. 31% ， P = 0. 043) ，a shorter median overall survival time (9 months vs 20 months，P = 0. 026) ，a lower proportion of ef- fector T cells［( 1. 39 ± 0. 12) % vs (3. 56 ± 0. 46) % ，P = 0. 038］，and a higher proportion of leukemia stem cells
［( 13. 82 ± 3. 66) % vs (3. 87 ± 1. 40) % ，P = 0. 021］．
Conclusion : PTPN11 gene mutation is a poor prognostic marker for AML．Those patients have a high early mortality rate ，low complete remission rate ，high recurrence rate，short median overall survival time，a low proportion of effector T cells，and a high proportion of leukemia stem cells.
- Full text:2024091416375708370PTPN11基因突变急性髓...血病患者临床特征及预后分析_陶千山.pdf
